Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,659,912,037.16, representing a 1.18% increase compared to CNY 1,640,533,883.14 in the same period last year[26]. - The net profit attributable to shareholders of the listed company reached CNY 270,761,313.68, a 20.37% increase from CNY 224,940,090.11 in the previous year[26]. - The net profit after deducting non-recurring gains and losses was CNY 228,776,613.49, up 27.94% from CNY 178,817,734.03 in the same period last year[26]. - Basic and diluted earnings per share were both CNY 0.34, reflecting a 21.43% increase from CNY 0.28 in the same period last year[26]. - The net cash flow from operating activities decreased by 66.30% to CNY 68,616,453.73 from CNY 203,613,813.95 in the previous year[26]. - Total assets at the end of the reporting period were CNY 5,508,319,658.93, a decrease of 2.79% from CNY 5,666,246,990.95 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company increased by 1.53% to CNY 3,977,480,700.93 from CNY 3,917,602,965.69 at the end of the previous year[26]. Investment and R&D - The company is increasing investment in R&D and marketing, particularly in the neurological and digestive business lines[26]. - The company holds a total of 173 patents, including 121 invention patents, reflecting strong R&D capabilities and innovation[53]. - The R&D team consists of over 700 technical personnel, with more than 200 holding master's or doctoral degrees, indicating a robust professional foundation[54]. - Research and development investment increased by 12.09% to approximately 155 million yuan, driven by accelerated innovation projects[73]. - The company is advancing the development of innovative drugs, with several projects in various clinical trial phases, including EVT201 and JX11502MA[49]. Market Position and Strategy - The company maintains a strong market position, ranking 40th in the 2020 China Pharmaceutical Industry Top 100, an improvement of 2 places from the previous year[48]. - The company is recognized as a leading enterprise in the cardiovascular and neurological fields, being one of the first "pioneering enterprises in the internationalization of pharmaceutical formulations" in China[48]. - The company’s sales strategy includes both domestic and international markets, with a focus on direct sales and partnerships with certified pharmaceutical companies[45]. - The pharmaceutical industry remains a high-growth sector, driven by aging populations and increasing healthcare demands, providing a favorable outlook for the company[37]. - The company aims to continue focusing on the mental and cardiovascular fields, enhancing product lines and competitiveness through internal and external resource integration[69]. Product and Sales Performance - The company’s main products include cardiovascular drugs such as Rosuvastatin and Simvastatin, and neurological drugs like Carbamazepine and Memantine, which are essential for treating various health conditions[38]. - In the CNS field, sales revenue reached 258 million RMB, marking a 33% increase compared to the previous year, capturing 80% of the hospital market share[64]. - The CV segment reported a sales revenue of 265 million RMB, a decline of 42.82% year-on-year, primarily due to price reductions from centralized procurement[65]. - The digestive line achieved a sales revenue of 239 million RMB, with a year-on-year growth of 35%, and self-operated business revenue increased by 58%[66]. - Internet e-commerce sales surged by 270% year-on-year, indicating significant growth potential in this channel[66]. Financial Management and Capital Structure - The company raised a total of 500 million yuan through a non-public offering of A-shares at an adjusted price of 7.40 yuan per share, increasing the number of shares issued to 67,567,567[142]. - The company reported rental income of 14.22 million yuan during the reporting period, contributing to over 10% of the total profit[152]. - The company has invested a total of 124 million yuan in entrusted wealth management products, with no overdue amounts or impairment losses reported[154]. - The total number of shares increased from 705,507,776 to 837,751,371 after a capital reserve distribution of 132,243,595 shares[164]. - The company's total share capital increased from 705,507,776 shares to 837,751,371 shares following the implementation of the 2020 annual equity distribution plan[168]. Environmental Management - The company has a comprehensive environmental management strategy, ensuring compliance with pollution discharge standards, with no exceedances reported for major pollutants[112][113]. - The company has installed online monitoring equipment for COD, ammonia nitrogen, pH, TOC, and flow, which is connected to environmental protection departments[116]. - The company has constructed two standard solid waste temporary storage facilities covering approximately 1,100 m² for hazardous solid waste disposal[116]. - The company’s wastewater treatment meets the comprehensive discharge standards, with the wastewater treatment process including oil separation, flotation, and three-stage biological treatment[118]. - The company has achieved stable operation of pollution control facilities, with pollutants meeting discharge standards and no environmental pollution incidents reported[120]. Risks and Challenges - The company faces significant risks including industry policy changes, R&D risks, environmental risks, and talent shortages, and is actively adjusting its strategies to mitigate these risks[98][99]. - There were no administrative penalties or significant litigation matters reported during the reporting period[134]. - The company has not engaged in any related party transactions or non-operating fund occupation during the reporting period[128].

证券代码：002020 证券简称：京新药业 公告编号：2021031 浙江京新药业股份有限公司 关于参加浙江辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，提升公司投资者关系管理水平，公司将 于 2021 年 5 月 13 日（星期四）15:00-17:00 参加 2021 年浙江辖区上市公司 投资者网上集体接待日活动， 投资者朋友可登陆"全景网·投资者关系互动平 台"（http://ir.p5w.net）参与本次交流。届时，公司副总裁兼财务总监陈美 丽女士、董事会秘书洪贇飞先生将通过互动平台与投资者进行网络沟通和交流， 欢迎广大投资者参加。 特此公告。 浙江京新药业股份有限公司董事会 2021 年 5 月 11 日 ...

Financial Performance - The company's operating revenue for Q1 2021 was ¥821,082,483.69, representing a 3.44% increase compared to ¥793,742,204.43 in the same period last year[9]. - Net profit attributable to shareholders was ¥129,356,741.25, a 35.22% increase from ¥95,666,199.21 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥99,513,713.36, up 25.12% from ¥79,533,640.22 in the previous year[9]. - Basic earnings per share increased by 53.85% to ¥0.20 from ¥0.13 in the same period last year[9]. - The weighted average return on equity rose to 3.25%, an increase of 0.62 percentage points from 2.63%[9]. - Total operating revenue for the current period reached ¥821,082,483.69, an increase from ¥793,742,204.43 in the previous period, representing a growth of approximately 3.4%[65]. - Net profit for the current period was ¥129,071,948.22, compared to ¥96,502,982.74 in the previous period, reflecting a significant increase of approximately 33.7%[70]. - Total comprehensive income for the current period was ¥129,214,477.34, compared to ¥96,753,682.92 in the previous period, reflecting an increase of approximately 33.4%[70]. - Total comprehensive income for the current period was ¥76,332,075.95, compared to ¥69,585,952.89 in the previous period[77]. Cash Flow - The net cash flow from operating activities decreased by 33.08% to ¥81,555,730.34 from ¥121,862,146.77 in the previous year[9]. - Net cash flow from investing activities increased by 170.21% year-on-year, mainly due to increased cash received from investment recoveries[26]. - The net increase in cash and cash equivalents rose by 39.22% year-on-year, primarily due to increased cash received from investment recoveries[26]. - The ending balance of cash and cash equivalents increased by 102.09% year-on-year, mainly due to increased cash received from investment recoveries[29]. - Cash flow from operating activities generated a net amount of ¥81,555,730.34, down 33.1% from ¥121,862,146.77 in the previous period[81]. - Cash flow from investing activities showed a net inflow of ¥195,229,381.21, compared to a net outflow of ¥278,056,622.69 in the previous period[81]. - Cash and cash equivalents at the end of the period totaled ¥985,479,476.64, an increase from ¥487,655,058.71 at the end of the previous period[84]. - The company received ¥550,000,000.00 from investment recoveries, up from ¥389,161,518.55 in the previous period[81]. - Operating cash flow net amount increased to ¥121,599,921.00 from a negative ¥51,961,385.83 in the previous period, representing a significant turnaround[85]. - Total cash inflow from operating activities reached ¥808,374,540.95, up 68.1% from ¥480,629,605.57 in the prior period[85]. - Cash outflow from investment activities decreased to ¥240,173,391.10 from ¥616,806,029.96, indicating improved cash management[88]. - Net cash flow from investment activities was ¥266,435,348.62, a recovery from a negative cash flow of ¥188,871,161.12 in the previous period[88]. - Cash and cash equivalents at the end of the period totaled ¥837,492,064.79, up from ¥166,502,649.52, marking a substantial increase[88]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,606,221,217.38, a decrease of 1.06% from ¥5,666,246,990.95 at the end of the previous year[9]. - Total liabilities decreased from ¥1,733,577,519.82 to ¥1,520,220,086.55, a decline of approximately 12.30%[53]. - Current liabilities decreased from ¥1,546,858,959.40 to ¥1,313,365,004.32, a decline of approximately 15.08%[53]. - Total equity increased from ¥3,932,669,471.13 to ¥4,086,001,130.83, an increase of approximately 3.90%[56]. - Total assets decreased from ¥5,666,246,990.95 to ¥5,606,221,217.38, a decline of approximately 1.06%[56]. - Non-current assets increased from ¥2,541,232,696.18 to ¥2,802,370,726.20, an increase of approximately 10.27%[56]. - Cash and cash equivalents increased from ¥637,623,564.83 to ¥878,592,449.86, an increase of approximately 37.83%[57]. - Accounts receivable increased from ¥122,751,491.60 to ¥190,667,560.68, an increase of approximately 55.31%[57]. - Inventory increased from ¥143,558,211.15 to ¥153,597,506.33, an increase of approximately 6.67%[57]. - Long-term equity investments remained stable at ¥1,177,544,358.03, showing a slight increase from ¥1,177,044,358.03[60]. - Other non-current assets increased significantly from ¥149,669,034.48 to ¥306,075,291.12, an increase of approximately 104.00%[60]. - The company reported a total liability of CNY 1,357,757,439.20, with current liabilities at CNY 1,200,857,380.97 and non-current liabilities at CNY 156,900,058.23[99]. Investments and Funding - The company plans to raise a total of 500 million yuan through a non-public stock issuance to fund projects aimed at enhancing production capacity and digital workshop construction[30]. - The company utilized 19 million yuan of idle raised funds and 98 million yuan of idle self-owned funds for entrusted financial management[38]. - The company has no violations regarding external guarantees during the reporting period[39]. - The company’s long-term equity investments were valued at CNY 1,177,044,358.03, reflecting its commitment to strategic investments[99]. - The company received cash from investment recovery of ¥490,000,000.00, an increase from ¥389,161,518.55 in the previous period[88]. Research and Development - Research and development expenses rose to ¥77,253,712.63 from ¥66,227,053.39, indicating an increase of about 16.0%[68]. - Research and development expenses rose to ¥41,537,942.56, up 12.8% from ¥36,959,346.77 in the previous period[74]. Other Financial Metrics - The company reported a financial expense income of -¥6,726,788.98, compared to -¥2,842,619.09 in the previous period, indicating a worsening of financial expenses[68]. - Other income decreased from ¥21,856,411.09 to ¥14,653,506.07, a decline of approximately 33.0%[68]. - The company has not audited its first-quarter report for 2021, indicating a potential area for investor scrutiny[102].

Financial Performance - The company's operating revenue for 2020 was CNY 3,258,075,481.25, a decrease of 10.66% compared to 2019[23] - The net profit attributable to shareholders for 2020 was CNY 653,070,206.69, an increase of 25.49% year-on-year[23] - The net profit after deducting non-recurring gains and losses was CNY 446,243,001.41, reflecting a growth of 5.97% from the previous year[23] - The basic earnings per share for 2020 was CNY 0.98, up 34.25% from CNY 0.73 in 2019[23] - The weighted average return on equity increased to 17.38%, up by 2.97 percentage points from 14.41% in 2019[23] - The net cash flow from operating activities was CNY 513,210,535.56, a decrease of 4.13% compared to the previous year[23] - Quarterly revenue for Q4 was ¥822,354,716.04, with a total annual revenue of ¥3,258,075,481.25[29] - Net profit attributable to shareholders for Q4 reached ¥280,520,108.59, marking a significant increase compared to previous quarters[29] Revenue Breakdown - The company reported a total of CNY 3,646,683,905.76 in operating revenue for 2019, which serves as a comparative benchmark for 2020[23] - The company’s main business revenue was CNY 3.21 billion, accounting for 98.64% of total operating revenue, with a year-on-year decrease of 10.84%[71] - The sales revenue from the neuropsychiatric product line reached approximately CNY 413 million, representing a year-on-year growth of 48%[62] - The cardiovascular product line generated sales revenue of CNY 793 million, a decrease of 31% year-on-year due to price reductions from centralized procurement[64] - The digestive product line achieved sales revenue of CNY 404 million, a decline of 3% year-on-year, but showed a recovery trend with over 20% growth in Q4[65] - The company’s raw material drug segment achieved sales revenue of CNY 803 million, a decline of 14.46% year-on-year, primarily due to price reductions from centralized procurement[67] Research and Development - The company has maintained its commitment to research and development, focusing on new products and technologies to drive future growth[6] - The company invested CNY 259 million in R&D during the reporting period, focusing on enhancing project initiation capabilities and clinical trial management efficiency[59] - The company has over 30 innovative and generic drug projects under research as of the end of 2020, with plans to add at least 10 new innovative drug projects in the next 3 years[121] - The company aims to launch 1 new innovative drug product and has 5 innovative drugs at different clinical stages[121] - The company will continue to increase investment in R&D for innovative drugs, consistency evaluation of generic drugs, and research on traditional Chinese medicine[121] - The company has a history of cash dividend distribution, with a total cash dividend of 432,411,892.00 RMB in 2020, which is 66.21% of the net profit attributable to ordinary shareholders[161] Assets and Investments - Total assets increased by 0.73% to ¥5,666,246,990.95 compared to the previous year[26] - Net assets attributable to shareholders rose by 5.99% to ¥3,917,602,965.69 year-on-year[26] - The company reported a significant increase in cash reserves, with cash and cash equivalents rising from ¥493,219,297.58 at the beginning of the year to ¥915,349,298.13[98] - The total investment amount for the reporting period was CNY 20,000,000, representing a 100% increase compared to the same period last year[105] - The company made a significant equity investment of CNY 20,000,000 in Hangzhou Niuquxing Biotechnology Co., Ltd., acquiring a 14.29% stake[105] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.5 per 10 shares, totaling CNY 231,425,000.30 based on 661,217,978 shares[6] - The company distributed cash dividends of 231,426,292.30 RMB in 2020, accounting for 35.44% of the net profit attributable to ordinary shareholders[161] - The cash dividend for 2018 was 206,127,985.80 RMB, which accounted for 55.82% of the net profit attributable to ordinary shareholders[161] - The company has a cash dividend distribution ratio of at least 40% in its profit distribution plan, reflecting its mature development stage and significant capital expenditure arrangements[162] Market and Competitive Position - The company is focused on expanding its product lines in cardiovascular and neurological medications, maintaining its position in the pharmaceutical industry[39] - The company aims to enhance its market presence and innovation in the healthcare sector, aligning with national healthcare reforms[39] - The company has established a complete pharmaceutical industry chain from raw materials to finished products, enhancing cost advantages and market competitiveness[47] - The company has built a comprehensive marketing network covering commercial channels, retail pharmacies, and hospital clinics across the country[53] Risk Management and Compliance - The company is facing risks related to industry policy changes, R&D challenges, environmental regulations, and talent shortages, and is actively adjusting strategies to mitigate these risks[148][149] - The company plans to maintain a focus on environmental safety and quality in its operations to meet increasing regulatory standards[149] - The company has implemented a talent development strategy to ensure alignment between management capabilities and business growth needs[149] - The company has complied with regulations regarding the disclosure of the use and storage of raised funds, with no violations reported[121] Corporate Governance - The company’s financial statements were audited by Lixin Certified Public Accountants, with a continuous service period of 10 years[179] - The company reported no significant accounting errors that required retrospective restatement during the reporting period[177] - The company did not experience any major litigation or arbitration matters during the reporting period[183] - The company has not faced any penalties or rectification issues during the reporting period[184]

Financial Performance - Operating revenue for the reporting period was CNY 795,186,882.07, down 15.13% year-on-year, while year-to-date revenue was CNY 2,435,720,765.21, a decrease of 12.87%[9]. - Net profit attributable to shareholders for the reporting period was CNY 147,610,007.99, a decline of 9.55%, with year-to-date net profit at CNY 372,550,098.11, down 23.81%[9]. - Basic earnings per share for the reporting period were CNY 0.2036, a decrease of 14.02%, while year-to-date earnings per share were CNY 0.5231, down 26.27%[9]. - The weighted average return on equity was 3.92%, a decrease of 0.59 percentage points from the previous year[9]. - The net profit for the current period is ¥147,619,334.21, a decrease from ¥163,159,997.11 in the previous period, representing a decline of approximately 9.5%[84]. - The total operating revenue for the current period is ¥445,039,719.65, down from ¥490,226,296.00 in the previous period, indicating a decrease of about 9.2%[88]. - The operating profit for the current period is ¥82,778,889.77, compared to ¥108,945,061.35 in the previous period, reflecting a decline of approximately 24%[88]. - The total profit for the current period is CNY 433,076,648.11, a decrease of 23.8% compared to CNY 568,519,766.85 in the previous period[95]. - The company's total comprehensive income for the current period is CNY 373,806,112.28, down from CNY 477,448,225.01 in the previous period[99]. Cash Flow - The net cash flow from operating activities was CNY 275,271,112.03, an increase of 171.67% compared to the same period last year[9]. - The net cash flow from operating activities for the current period is approximately ¥478.88 million, an increase of 15.1% compared to ¥415.88 million in the previous period[106]. - Cash inflow from investment activities totaled approximately ¥2.34 billion, compared to ¥2.24 billion in the previous period, reflecting a growth of 4.9%[109]. - The net cash flow from investment activities improved significantly to approximately ¥124.64 million, compared to a negative cash flow of ¥311.99 million in the previous period[109]. - The cash flow from financing activities resulted in a net outflow of approximately ¥447.96 million, worsening from a net outflow of ¥149.24 million in the previous period[109]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,463,793,441.55, a decrease of 2.87% compared to the end of the previous year[9]. - The total current assets decreased to ¥3.19 billion from ¥3.49 billion, representing a decline of 8.4% year-over-year[59]. - The company's total liabilities decreased to ¥1.81 billion from ¥1.91 billion, a reduction of 4.5% compared to the previous year[65]. - The total assets of the company as of September 30, 2020, were ¥5.46 billion, down from ¥5.63 billion at the end of 2019, indicating a decrease of 3.0%[68]. - Current liabilities were reported at CNY 1,770,292,227.81, while total liabilities reached CNY 1,914,376,310.28[123]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,109, with the top ten shareholders holding a significant portion of shares[13]. - The largest shareholder, Lü Gang, held 20.55% of the shares, amounting to 148,997,296 shares, with a portion pledged[13]. - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[16]. - The company repurchased a total of 19,364,224 shares, accounting for 2.67% of the total share capital, with a total payment of ¥200.99 million[42]. Investment Activities - The company raised a total of up to ¥500 million through a non-public offering of A-shares, with the number of shares issued not exceeding 54,824,561[39]. - The company reported a net cash outflow from investing activities of ¥124.64 million, a 139.95% decrease compared to the previous year, primarily due to reduced cash outflows from investment activities[38]. - The company recorded investment income of CNY 60,823,121.04, a decrease of 35.9% from CNY 94,894,551.83 in the previous period[95]. Expenses - Total operating costs for the period were CNY 667,952,298.68, down from CNY 795,035,290.10 in the previous period[80]. - Research and development expenses decreased to CNY 44,709,362.74 from CNY 81,247,157.55 year-over-year[80]. - The management expenses increased to CNY 131,010,704.97, up 22.1% from CNY 107,220,538.44 in the previous period[95]. - The tax expenses for the current period are ¥17,525,838.68, compared to ¥12,677,217.45 in the previous period, an increase of about 38.4%[88].

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,640,533,883.14, a decrease of 11.73% compared to the same period last year[23]. - The net profit attributable to shareholders was CNY 224,940,090.11, down 30.95% year-on-year[23]. - The net cash flow from operating activities was CNY 203,613,813.95, reflecting a decline of 35.27% compared to the previous year[23]. - Basic earnings per share decreased by 33.09% to CNY 0.3158[23]. - Total assets at the end of the reporting period were CNY 5,441,437,473.75, a decrease of 3.26% from the end of the previous year[23]. - The net assets attributable to shareholders decreased by 5.58% to CNY 3,489,979,312.21[23]. - The weighted average return on equity was 6.78%, down 2.23 percentage points from the previous year[23]. - The company achieved sales revenue of 1.641 billion yuan, a year-on-year decrease of 11.73%[38]. - Net profit attributable to the listed company was 225 million yuan, down 30.95% year-on-year[38]. Sales and Revenue Breakdown - Finished drug sales revenue for the first half was 1.002 billion yuan, a decrease of 8% year-on-year, with the psychiatric and neurological field growing by 55% to 194 million yuan[39]. - The cardiovascular category saw sales revenue of 463 million yuan, down 21% due to price reductions from centralized procurement[39]. - The company’s raw material drug sales revenue was 417 million yuan, a decrease of 22% year-on-year, with quinolone raw materials achieving a 13% increase to 342 million yuan[39]. - Medical device sales revenue was 205 million yuan, down 6% year-on-year, primarily due to order cancellations or delays in international ODM business[39]. Assets and Investments - The company’s fixed assets increased by 259.19 million yuan, a rise of 0.29% due to increased equipment purchases[41]. - The company’s intangible assets decreased by 959.83 million yuan, a reduction of 5.76% due to amortization[41]. - The company’s construction in progress increased by 4,697.54 million yuan, an increase of 86.52% due to the expansion of the production facility[41]. - The total investment during the reporting period was CNY 20,000,000, a decrease of 62.83% compared to CNY 53,806,786.83 in the same period last year[86]. - The company made a significant equity investment of CNY 20,000,000 in Hangzhou Niuquxing Biotechnology Co., Ltd., acquiring a 14.29% stake[86]. Research and Development - The company holds a total of 95 domestic invention patents and 4 US invention patents, showcasing strong R&D capabilities[49]. - The company is actively enhancing its product pipeline by introducing integrated artificial blood vessel products and ketogenic products for epilepsy, aiming for synergy in the cardiovascular and neurological fields[65]. - The company has a professional R&D team of nearly 700 people, with over 30% holding master's or doctoral degrees[50]. - The company is committed to building a research team to enhance the quality and efficiency of drug development projects[114]. Corporate Strategy and Future Plans - The company aims to strengthen its core business in pharmaceuticals while expanding into the medical device sector, enhancing its future profitability and risk resistance[48]. - The company has initiated the establishment of a full subsidiary in Shandong to enhance its fine chemical business and improve production capacity and cost advantages[66]. - The company has implemented a project to enhance the production efficiency of its core product, which is expected to meet market demand for the next 3-5 years[100]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company held its first extraordinary shareholders' meeting on February 5, 2020, with a participation rate of 32.34%[118]. - The annual shareholders' meeting for 2019 took place on April 22, 2020, with a participation rate of 35.22%[118]. - The company has implemented two employee stock ownership plans in 2019, with a total of 2,899,259 shares transferred to the first plan, accounting for 0.40% of the total share capital[128]. - The second employee stock ownership plan involved the transfer of 1,496,565 shares, representing 0.21% of the total share capital[129]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[156]. - The total COD emissions from the company were 70.037 tons, which is below the approved total of 251.73 tons, indicating no exceedance[156]. - The company has implemented effective waste gas treatment systems, ensuring compliance with emission standards[157]. - The wastewater treatment capacity is 2,400 tons per day, with all wastewater treated to meet discharge standards[157]. - The company conducts regular monitoring of pollutants, ensuring compliance with environmental regulations[169]. Risk Management - The company faced various risks and has outlined measures to address them in the report[6]. - The company is facing risks from industry policy changes, including price reductions and procurement reforms, which may impact the survival of domestic generic drug companies[114]. - The impact of the COVID-19 pandemic has affected the company's operations, but it has taken measures to resume normal production while ensuring compliance with health regulations[115]. - The company has implemented measures to address talent shortages by focusing on internal training and external recruitment to meet development needs[115].

证券代码：002020 证券简称：京新药业 公告编号：2020044 浙江京新药业股份有限公司 关于参加浙江辖区上市公司投资者网上集 体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，浙江京新药业股份有限公司（以下简称 "公司"）将参加由浙江证监局指导、浙江上市公司协会与深圳市全景网络有限 公司共同举办的"凝心聚力 共克时艰"辖区上市公司投资者网上集体接待日活 动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景.路演天下"网站（http://rs.p5w.net）参 与公司本次投资者网上接待日活动。网上互动交流时间为 2020 年 5 月 15 日 星期五）15:00-17:00。 届时公司副总裁兼财务总监陈美丽女士、董事会秘书洪贇飞先生将采用网络 远程方式与投资者就公司治理、发展战略、经营状况、可持续发展等问题进行沟 通（如有特殊情况，参与人员会有调整）。 欢迎广大投资者积极参与。 特此公告。 浙江京新药业股份有限公司董事会 二 O ...

Financial Performance - The company's operating revenue for Q1 2020 was ¥793,742,204.43, a decrease of 11.15% compared to ¥893,372,399.42 in the same period last year[9] - Net profit attributable to shareholders was ¥95,666,199.21, down 27.18% from ¥131,379,249.16 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥79,533,640.22, a decrease of 15.60% compared to ¥94,231,955.93 in the previous year[9] - Basic and diluted earnings per share were both ¥0.1329, down 29.87% from ¥0.1895 in the previous year[9] - Total revenue for the current period is ¥793,742,204.43, a decrease of 11.2% compared to ¥893,372,399.42 in the previous period[76] - Net profit for the current period is ¥96,502,982.74, a decrease of 26.7% from ¥131,530,009.98 in the previous period[83] - Operating profit decreased to ¥76,490,200.26, down 34.7% from ¥117,331,987.97 in the previous period[87] - Total comprehensive income for the current period is ¥69,585,952.89, compared to ¥105,784,721.57 in the previous period[90] Cash Flow - The net cash flow from operating activities increased by 76.02% to ¥121,862,146.77 from ¥69,232,593.75 in the same period last year[9] - Cash flow from operating activities generated a net amount of ¥121,862,146.77, an increase of 76.2% from ¥69,232,593.75 in the previous period[91] - Net cash flow from financing activities increased by 3762.44% to ¥227,635,340.82, primarily due to an increase in cash received from borrowings[40] - Financing activities generated a net cash inflow of ¥227,635,340.82, compared to a net outflow of ¥6,215,408.54 in the previous period[97] - Investment activities resulted in a net cash outflow of ¥278,056,622.69, worsening from a net outflow of ¥100,485,380.69 in the previous period[94] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,841,770,264.99, an increase of 3.85% from ¥5,625,088,046.03 at the end of the previous year[9] - Total liabilities increased to CNY 2,105,001,046.32 from CNY 1,914,376,310.28, representing a growth of about 9.93%[64] - Total current liabilities amounted to CNY 1,961,932,464.72, an increase from CNY 1,770,292,227.81, reflecting a growth of about 10.80%[64] - Total assets amounted to CNY 4,862,688,352.78, with current assets at CNY 2,544,359,556.59 and non-current assets at CNY 2,318,328,796.19[111] Shareholder Equity - Net assets attributable to shareholders were ¥3,722,181,288.11, a slight increase of 0.71% from ¥3,696,079,802.35 at the end of the previous year[9] - The company's equity attributable to shareholders reached CNY 3,722,181,288.11, up from CNY 3,696,079,802.35, an increase of approximately 0.71%[67] - The company has a total of CNY 3,710,711,735.75 in total equity, including minority interests of CNY 14,631,933.40[108] Expenses - Total operating costs for the current period are ¥707,217,154.49, down 8.7% from ¥774,883,655.75 in the previous period[79] - Research and development expenses for the current period are ¥66,227,053.39, an increase from ¥51,043,288.08 in the previous period[79] - The company reported a decrease in sales expenses to ¥159,789,393.41, down 1.1% from ¥161,588,371.99 in the previous period[87] Other Financial Metrics - The weighted average return on equity decreased by 1.04 percentage points to 2.63% from 3.67% in the previous year[9] - The company reported a non-operating income of ¥16,132,558.99 during the reporting period[9] - Other income increased by 144.26% to ¥14,124,151.09, primarily due to an increase in government subsidies[31] - The company received 200,000,000.00 CNY in loans during the financing activities, indicating a reliance on debt financing[101] Miscellaneous - The company established a wholly-owned subsidiary in Shandong Province with an investment of ¥12,000,000 to promote the orderly implementation of the Weifang project[42] - The first quarter report for 2020 was not audited[114]

Financial Performance - The company's operating revenue for 2019 was CNY 3,646,683,905.76, representing a 23.88% increase compared to CNY 2,943,801,995.73 in 2018[21] - The net profit attributable to shareholders of the listed company reached CNY 520,396,181.46, a 40.92% increase from CNY 370,036,653.03 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 421,098,548.74, up 33.53% from CNY 316,121,885.58 in 2018[21] - The basic earnings per share increased to CNY 0.729, reflecting a growth of 42.66% from CNY 0.512 in the previous year[21] - The net cash flow from operating activities was CNY 535,301,257.28, showing a slight increase of 2.36% compared to CNY 523,403,340.87 in 2018[21] - Total assets increased by 12.10% year-over-year, reaching CNY 5,625,088,046.03 at the end of 2019[25] - The return on equity (ROE) was 14.41%, an increase of 4.64 percentage points from the previous year[56] - The gross profit margin for the main business was 65.03%, with a year-on-year increase of 0.34%[69] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.50 per 10 shares (including tax) to all shareholders[5] - The total cash dividends distributed in 2019 accounted for 45.18% of the net profit attributable to ordinary shareholders, which was 520,396,181.46 RMB[137] - The cash dividend distribution policy is based on the total share capital on the record date, excluding repurchased shares[132] - The cash dividends for the last three years have shown a consistent increase, reflecting the company's commitment to returning value to shareholders[137] Business Operations and Strategy - The company continues to focus on the research and development of chemical preparations, traditional Chinese medicine, and medical devices[36] - The company aims to strengthen its pharmaceutical business while expanding into the medical device sector[40] - The company is recognized as a leading enterprise in the internationalization of Chinese pharmaceutical formulations[40] - The company has maintained a strong growth trajectory despite the overall slowdown in the pharmaceutical industry[39] - The company has established a complete pharmaceutical industry chain, enhancing cost advantages and market competitiveness[46] - The company has expanded its marketing network across commercial channels, retail pharmacies, and clinical hospitals, enhancing brand recognition and influence[52] Research and Development - The company has a total of 142 valid patents, including 94 domestic invention patents and 3 US invention patents, reflecting strong R&D capabilities[47][48] - The company has made significant progress in its R&D pipeline, with five products in the psychiatric and neurological field and three in the cardiovascular field currently under development[62] - The company has submitted registration applications for seven generic drug products, with four products already approved, including Rosuvastatin calcium dispersible tablets and Levetiracetam oral solution[63] Market Performance - Sales in the cardiovascular product category amounted to ¥1.11 billion, while sales in the psychiatric and neurological products reached ¥272 million, and gastrointestinal products totaled ¥417 million, indicating a continuous increase in market share across these therapeutic areas[57] - The company achieved over 50% market share in the domestic medical imaging display terminal market, with more than 8,000 terminal hospital users[61] Financial Management - The company reported a total of CNY 4,981.14 million invested in the annual production expansion project of solid preparations during the reporting period[94] - The company has committed to a total investment of CNY 15,071.02 million for the traditional Chinese medicine comprehensive preparation technology transformation project, with only CNY 620.75 million invested to date, indicating a progress of 4.12%[94] - The company has not made any significant equity investments during the reporting period[91] - The company has not changed the purpose of the raised funds during the reporting period, maintaining the original investment commitments[93] Compliance and Governance - The company has committed to strict compliance with regulations regarding the transfer of shares and related party transactions[142] - The company has ensured that all related transactions comply with legal regulations and are conducted at fair market prices[142] - The company has not faced any major litigation or arbitration matters during the reporting period[160] Environmental Responsibility - The company has established a comprehensive environmental management system, certified by ISO14001, to ensure pollution control and compliance with national regulations[188] - The total discharge of COD from the company's facilities was 128.79 tons, which is below the approved limit of 263.28 tons, indicating no exceedance of discharge standards[193] - The company has invested in a wastewater treatment system with a daily capacity of 2400 tons, ensuring that all wastewater meets discharge standards[194] Employee Engagement and Welfare - The company has implemented a talent development system, including training programs and employee engagement initiatives[185] - The company emphasizes employee rights protection and has established a comprehensive internal control system to ensure fair treatment of all shareholders[182] - The company engaged in related party transactions, with a total transaction amount of 3,500,000 yuan for packaging materials, representing 35.65% of the same type of transactions[167]

Group 1: Event Details - Zhejiang Jingxin Pharmaceutical Co., Ltd. will participate in the "Communication Promotes Development, Rational Growth Together" online investor reception day event [2] - The event is guided by the Zhejiang Securities Regulatory Bureau and organized by the Zhejiang Listed Companies Association and Shenzhen Panorama Network Co., Ltd. [2] - The online interaction will take place on November 5, 2019, from 15:30 to 17:00 [2] Group 2: Participation and Communication - Company President and Board Secretary Jin Zhiping and Vice President and CFO Chen Meili will communicate with investors via remote online methods [2] - Investors are encouraged to actively participate in the event [2] Group 3: Assurance of Information Disclosure - The company and its board members guarantee the authenticity, accuracy, and completeness of the disclosed information, with no false records, misleading statements, or significant omissions [2]